Pfizer takes on Novartis, Lilly with Xeljanz psoriatic arthritis approval

15th December 2017 Uncategorised 0

For the second straight week, there’s a new psoriatic arthritis drug on the block. This week, that drug is Pfizer’s Xeljanz, which nabbed an FDA approval late Thursday to treat patients who haven’t adequately responded to or are intolerant of methotrexate or other disease-modifying medications.

More: Pfizer takes on Novartis, Lilly with Xeljanz psoriatic arthritis approval
Source: fierce